Array V. Rudakova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Array V. Rudakova has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
Yu. V. Lobzin
Federal Scientific and Clinical Center for Infectious Diseases; North-Western State Medical University named after. I.I. Mechnikov
12 shared publications- Leyla Seymurovna Namazova-Baranova
Russian Scientific Surgery Center named after Academician B.V. Petrovskiy with the Russian Academy of Sciences, Moscow, Russia
8 shared publications - Susanna M. Kharit
Federal Research and Clinical Center for Infectious Diseases; Saint Petersburg State Pediatric Medical University
8 shared publications - L. Yu. Drozdova
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
7 shared publications - Nikolay I. Briko
I.M. Sechenov First Moscow State Medical University (Sechenov University)
7 shared publications - Oksana Mikhailovna Drapkina
National Medical Research Center for Therapy and Preventive Medicine, Ministry of Health of Russia
7 shared publications
Latest Publications
- Open Access
- 31 July 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (6) , 4925
Pneumococcal infection in the elderly: cost-effectiveness of vaccination to reduce demographic losses
Aim . To assess cost-effectiveness for vaccinating people ≥60 years against pneumococcal infection. Material and methods . Markov modeling was conducted using epidemiological data for the Russian Federation for people aged ≥60 years. The cost-effectiveness of monovaccination with a 23-valent polysaccharide vaccine (PPV23), sequential immunization with a 13-valent conjugate vaccine (PCV13) followed by PPV23 one year later, and vaccination with a 20-valent conjugate vaccine (PCV20) were assessed. The analysis was conducted from the perspective of society as a whole and from the healthcare system. The study time horizon was 10 years. Vaccine costs were analyzed based on registered prices, including VAT. Costs and quality-adjusted life expectancy were discounted by 3% per year. A sensitivity analysis assessed the cost-effectiveness of changing the price of PCV20 by 15% and reducing the time horizon to 5 years. Results . PCV20 vaccination reduces the incidence of pneumococcal infection compared to monovaccination with PPV23 and sequential PCV13/PPV23 immunization. When vaccinating individuals ≥60 years, the incremental cost per additional quality-adjusted life year (QALY) from a societal perspective would be RUB3,684,400, RUB2,087,300, and RUB1,385,600 for PPV23, PCV13/PPV23, and PCV20 vaccination, respectively. When analyzed from a healthcare system perspective, the cost-effectiveness ratios are RUB3,908,100/QALY, RUB2,288,700/ QALY, and RUB1,585,300/QALY for vaccination with PPV23, PCV13/ PPV23, and PCV20, respectively. A sensitivity analysis demonstrated the reliability of the obtained data. Conclusion . Vaccination of Russian people aged ≥60 years with PCV20 provides the greatest reduction in pneumococcal infection incidence and is highly cost-effective compared to PPV23 vaccination and is cost-effective compared to sequential PCV13/PPV23 vaccination. All vaccination options are cost-effective compared to no vaccination.
- 31 July 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (6) , 4925
Open AccessPneumococcal infection in the elderly: cost-effectiveness of vaccination to reduce demographic losses
Aim . To assess cost-effectiveness for vaccinating people ≥60 years against pneumococcal infection. Material and methods . Markov modeling was conducted using epidemiological data for the Russian Federation for people aged ≥60 years. The cost-effectiveness of monovaccination with a 23-valent polysaccharide vaccine (PPV23), sequential immunization with a 13-valent conjugate vaccine (PCV13) followed by PPV23 one year later, and vaccination with a 20-valent conjugate vaccine (PCV20) were assessed. The analysis was conducted from the perspective of society as a whole and from the healthcare system. The study time horizon was 10 years. Vaccine costs were analyzed based on registered prices, including VAT. Costs and quality-adjusted life expectancy were discounted by 3% per year. A sensitivity analysis assessed the cost-effectiveness of changing the price of PCV20 by 15% and reducing the time horizon to 5 years. Results . PCV20 vaccination reduces the incidence of pneumococcal infection compared to monovaccination with PPV23 and sequential PCV13/PPV23 immunization. When vaccinating individuals ≥60 years, the incremental cost per additional quality-adjusted life year (QALY) from a societal perspective would be RUB3,684,400, RUB2,087,300, and RUB1,385,600 for PPV23, PCV13/PPV23, and PCV20 vaccination, respectively. When analyzed from a healthcare system perspective, the cost-effectiveness ratios are RUB3,908,100/QALY, RUB2,288,700/ QALY, and RUB1,585,300/QALY for vaccination with PPV23, PCV13/ PPV23, and PCV20, respectively. A sensitivity analysis demonstrated the reliability of the obtained data. Conclusion . Vaccination of Russian people aged ≥60 years with PCV20 provides the greatest reduction in pneumococcal infection incidence and is highly cost-effective compared to PPV23 vaccination and is cost-effective compared to sequential PCV13/PPV23 vaccination. All vaccination options are cost-effective compared to no vaccination.
- Open Access
- 17 December 2025
- Published by ECO-Vector LLC (Publications) in Russian Family Doctor
- Vol. 29 (4) , 53-59
Secondary prevention of congenital cytomegalovirus infection with valacyclovir: pharmacoeconomic aspects
BACKGROUND: Congenital cytomegalovirus infection is associated with an increased risk of congenital malformations and neonatal disability, resulting in reduced quality of life for both the child and the mother. Therefore, secondary prevention of congenital cytomegalovirus infection remains highly relevant. AIM: This work aimed to evaluate the cost-effectiveness of valacyclovir therapy for primary cytomegalovirus infection in pregnant women during the first trimester for the prevention of congenital cytomegalovirus infection. METHODS: A model-based analysis with a 5-year time horizon was conducted from a societal perspective. The effectiveness of the intervention was derived from previously published double-blind randomized controlled trial data including women with primary cytomegalovirus infection in the first trimester of pregnancy. The model accounted for the probability of disability in children with congenital cytomegalovirus infection due to severe sensorineural hearing loss and neurodegenerative disorders. The impact of congenital cytomegalovirus infection on maternal and child quality of life was consistent with previously published data. Costs and quality-adjusted life years were discounted at an annual rate of 3%. RESULTS: Valacyclovir therapy is expected to reduce the proportion of children with disability resulting from congenital cytomegalovirus infection from 4.8% to 1.4% among all women with primary cytomegalovirus infection in the first trimester. Over a 5-year period, life expectancy increased by 0.172 quality-adjusted life years (QALY), whereas government expenditures decreased by 25.8 thousand rubles per patient with primary cytomegalovirus infection in the first trimester. Sensitivity analysis confirmed the robustness of the findings. CONCLUSION: Under the adopted assumptions, secondary prevention of congenital cytomegalovirus infection through valacyclovir therapy in pregnant women with primary cytomegalovirus infection during the first trimester leads not only to reduced neonatal mortality and disability but also to decreased healthcare budget expenditures.
- 17 December 2025
- Published by ECO-Vector LLC (Publications) in Russian Family Doctor
- Vol. 29 (4) , 53-59
Open AccessSecondary prevention of congenital cytomegalovirus infection with valacyclovir: pharmacoeconomic aspects
BACKGROUND: Congenital cytomegalovirus infection is associated with an increased risk of congenital malformations and neonatal disability, resulting in reduced quality of life for both the child and the mother. Therefore, secondary prevention of congenital cytomegalovirus infection remains highly relevant. AIM: This work aimed to evaluate the cost-effectiveness of valacyclovir therapy for primary cytomegalovirus infection in pregnant women during the first trimester for the prevention of congenital cytomegalovirus infection. METHODS: A model-based analysis with a 5-year time horizon was conducted from a societal perspective. The effectiveness of the intervention was derived from previously published double-blind randomized controlled trial data including women with primary cytomegalovirus infection in the first trimester of pregnancy. The model accounted for the probability of disability in children with congenital cytomegalovirus infection due to severe sensorineural hearing loss and neurodegenerative disorders. The impact of congenital cytomegalovirus infection on maternal and child quality of life was consistent with previously published data. Costs and quality-adjusted life years were discounted at an annual rate of 3%. RESULTS: Valacyclovir therapy is expected to reduce the proportion of children with disability resulting from congenital cytomegalovirus infection from 4.8% to 1.4% among all women with primary cytomegalovirus infection in the first trimester. Over a 5-year period, life expectancy increased by 0.172 quality-adjusted life years (QALY), whereas government expenditures decreased by 25.8 thousand rubles per patient with primary cytomegalovirus infection in the first trimester. Sensitivity analysis confirmed the robustness of the findings. CONCLUSION: Under the adopted assumptions, secondary prevention of congenital cytomegalovirus infection through valacyclovir therapy in pregnant women with primary cytomegalovirus infection during the first trimester leads not only to reduced neonatal mortality and disability but also to decreased healthcare budget expenditures.
- Open Access
- 18 October 2025
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 2 (3) , 135-262
Immunoprophylaxis. Guidelines (second edition)
Immunoprophylaxis is one of the most effective tools for reducing morbidity and mortality from infectious diseases. In the context of global epidemiological challenges and increased population mobility, the issues of managing immunization, proper patient selection, safety and effectiveness of vaccination are of particular importance. The document systematizes modern approaches to organizing and conducting vaccination of adults. It includes sections on planning and vaccination techniques, contraindications and "false contraindications", features of vaccination against specific infections (influenza, pneumococcal infection, hepatitis, diphtheria, tetanus, poliomyelitis, measles, rubella, etc.), as well as vaccination in pregnant women and military personnel. Particular attention is paid to the registration and treatment of post-vaccination reactions and complications, and the costeffectiveness of vaccination. The guidelines are intended for general practitioners, infectious disease specialists, epidemiologists, pediatricians, and public health specialists.
- 18 October 2025
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 2 (3) , 135-262
Open AccessImmunoprophylaxis. Guidelines (second edition)
Immunoprophylaxis is one of the most effective tools for reducing morbidity and mortality from infectious diseases. In the context of global epidemiological challenges and increased population mobility, the issues of managing immunization, proper patient selection, safety and effectiveness of vaccination are of particular importance. The document systematizes modern approaches to organizing and conducting vaccination of adults. It includes sections on planning and vaccination techniques, contraindications and "false contraindications", features of vaccination against specific infections (influenza, pneumococcal infection, hepatitis, diphtheria, tetanus, poliomyelitis, measles, rubella, etc.), as well as vaccination in pregnant women and military personnel. Particular attention is paid to the registration and treatment of post-vaccination reactions and complications, and the costeffectiveness of vaccination. The guidelines are intended for general practitioners, infectious disease specialists, epidemiologists, pediatricians, and public health specialists.
- Open Access
- 18 October 2025
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 2 (3) , 135-262
Immunoprophylaxis. Guidelines (second edition)
Immunoprophylaxis is one of the most effective tools for reducing morbidity and mortality from infectious diseases. In the context of global epidemiological challenges and increased population mobility, the issues of managing immunization, proper patient selection, safety and effectiveness of vaccination are of particular importance.The document systematizes modern approaches to organizing and conducting vaccination of adults. It includes sections on planning and vaccination techniques, contraindications and "false contraindications", features of vaccination against specific infections (influenza, pneumococcal infection, hepatitis, diphtheria, tetanus, poliomyelitis, measles, rubella, etc.), as well as vaccination in pregnant women and military personnel. Particular attention is paid to the registration and treatment of post-vaccination reactions and complications, and the costeffectiveness of vaccination.The guidelines are intended for general practitioners, infectious disease specialists, epidemiologists, pediatricians, and public health specialists.
- 18 October 2025
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 2 (3) , 135-262
Open AccessImmunoprophylaxis. Guidelines (second edition)
Immunoprophylaxis is one of the most effective tools for reducing morbidity and mortality from infectious diseases. In the context of global epidemiological challenges and increased population mobility, the issues of managing immunization, proper patient selection, safety and effectiveness of vaccination are of particular importance.The document systematizes modern approaches to organizing and conducting vaccination of adults. It includes sections on planning and vaccination techniques, contraindications and "false contraindications", features of vaccination against specific infections (influenza, pneumococcal infection, hepatitis, diphtheria, tetanus, poliomyelitis, measles, rubella, etc.), as well as vaccination in pregnant women and military personnel. Particular attention is paid to the registration and treatment of post-vaccination reactions and complications, and the costeffectiveness of vaccination.The guidelines are intended for general practitioners, infectious disease specialists, epidemiologists, pediatricians, and public health specialists.
- 28 July 2025
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 28 (7)
Vaccination against pneumococcal infection as a mean of reducing morbidity and mortality of the adult population from risk groups in the Russian Federation. (Resolution of the Council of Experts)
Pneumococcal diseases are a relevant issue of the practical healthcare. The increase in pneumococcal infection in the Russian Federation in recent years, especially among persons over 60 years old, causes the need to improve prevention measures for this infection. The highest level of morbidity with pneumococcal infection is recorded in adults with various health problems (with comorbid conditions) — diabetes mellitus, chronic heart failure, chronic obstructive pulmonary disease. Vaccination, which is the only way to significantly influence morbidity, mortality and reduce the growth of antibiotic resistance, is recognized as an effective method of pneumococcal infection prevention. Vaccine prophylaxis is one of the priority areas for implementation of the national policy on development of the health system in Russia. Special niche in the preventive continuum is immunoprophylaxis in persons, especially over 60 years old, belonging to risk groups. Meeting of the Experts Council on the «Vaccination against pneumococcal infection as a mean to reduce morbidity and mortality of adult population at risk in the Russian Federation» topic has taken place in Moscow on February 11, 2025 under the chairmanship of the academician of the RAS O.M. Drapkina and under the auspices of the Russian Society of Non-communicable Diseases Prevention (RSNCDP). The session was attended by the chief consultants of the Ministry of Health of Russia, leading experts in the field of therapy, cardiology, pulmonology, endocrinology, rheumatology, gerontology, preventive medicine, epidemiology, microbiology and antimicrobial resistance, infectious diseases, an expert in pharmacoeconomic research, who presented relevant problems and proposals for their solution in the context of the discussed topic in their reports. The resolution of the Experts Council is presented in this article.
- 28 July 2025
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 28 (7)
Vaccination against pneumococcal infection as a mean of reducing morbidity and mortality of the adult population from risk groups in the Russian Federation. (Resolution of the Council of Experts)
Pneumococcal diseases are a relevant issue of the practical healthcare. The increase in pneumococcal infection in the Russian Federation in recent years, especially among persons over 60 years old, causes the need to improve prevention measures for this infection. The highest level of morbidity with pneumococcal infection is recorded in adults with various health problems (with comorbid conditions) — diabetes mellitus, chronic heart failure, chronic obstructive pulmonary disease. Vaccination, which is the only way to significantly influence morbidity, mortality and reduce the growth of antibiotic resistance, is recognized as an effective method of pneumococcal infection prevention. Vaccine prophylaxis is one of the priority areas for implementation of the national policy on development of the health system in Russia. Special niche in the preventive continuum is immunoprophylaxis in persons, especially over 60 years old, belonging to risk groups. Meeting of the Experts Council on the «Vaccination against pneumococcal infection as a mean to reduce morbidity and mortality of adult population at risk in the Russian Federation» topic has taken place in Moscow on February 11, 2025 under the chairmanship of the academician of the RAS O.M. Drapkina and under the auspices of the Russian Society of Non-communicable Diseases Prevention (RSNCDP). The session was attended by the chief consultants of the Ministry of Health of Russia, leading experts in the field of therapy, cardiology, pulmonology, endocrinology, rheumatology, gerontology, preventive medicine, epidemiology, microbiology and antimicrobial resistance, infectious diseases, an expert in pharmacoeconomic research, who presented relevant problems and proposals for their solution in the context of the discussed topic in their reports. The resolution of the Experts Council is presented in this article.
- Open Access
- 15 March 2025
- Published by SPRIDA in Journal Infectology
- Vol. 17 (1) , 107-113
Cost-effectiveness of pertussis booster vaccination of 6-year-old children
Primary pertussis vaccination in the Russian Federation is carried out with 3 doses of the vaccine against diphtheria, whooping cough and tetanus at 3; 4.5 and 6 months. At 18 months, children are revaccinated against diphtheria, whooping cough and tetanus. At the age of 6-7 and 14 years, children are revaccinated against diphtheria and tetanus without the whooping cough component. Observational studies have shown that the clinical effectiveness of vaccination against whooping cough significantly decreases over time.The aim of the work is to assess the cost-effectiveness of revaccination of 6-year-old children against whooping cough infection.Material and methods. A modeling study of the cost-effectiveness of revaccination of 6-year-old children against whooping cough using an acellular vaccine was carried out from the societal perspective (direct medical and indirect costs were estimated) taking into account the herd effect of vaccination. The incidence of whooping cough and mortality associated with it corresponded to the official indicators of the Ministry of Health of the Russian Federation. In the base case the time horizon of the study is 12 years. The analysis of the costs of whooping cough therapy was carried out on the basis of the of the State Guarantees Program for the Free Provision of Medical Care to Citizens for 2024 and for the planning period of 2025 and 2026. Vaccination costs were calculated taking into account the weighted average price of the vaccine during government procurement in July-August 2024. Indirect costs were estimated based on gross domestic product (GDP) loss due to temporary disability of patients’ parents and death of patients. Costs and quality-adjusted life expectancy were discounted by 3% per year.Results. The incremental cost-effectiveness ratio (ICER) of revaccination of children aged 6 years against whooping cough is 205.110 thousand rubles / QALY. The volume of averted costs is 2.642 thousand rubles per vaccinated child, including 0.416 thousand rubles – averted direct medical costs and 2.226 thousand rubles – averted indirect costs.Conclusion. Taking into account the accepted assumptions, а booster dose of pertussis vaccine to 6-year-old children can be considered as a highly cost-effective intervention.
- 15 March 2025
- Published by SPRIDA in Journal Infectology
- Vol. 17 (1) , 107-113
Open AccessCost-effectiveness of pertussis booster vaccination of 6-year-old children
Primary pertussis vaccination in the Russian Federation is carried out with 3 doses of the vaccine against diphtheria, whooping cough and tetanus at 3; 4.5 and 6 months. At 18 months, children are revaccinated against diphtheria, whooping cough and tetanus. At the age of 6-7 and 14 years, children are revaccinated against diphtheria and tetanus without the whooping cough component. Observational studies have shown that the clinical effectiveness of vaccination against whooping cough significantly decreases over time.The aim of the work is to assess the cost-effectiveness of revaccination of 6-year-old children against whooping cough infection.Material and methods. A modeling study of the cost-effectiveness of revaccination of 6-year-old children against whooping cough using an acellular vaccine was carried out from the societal perspective (direct medical and indirect costs were estimated) taking into account the herd effect of vaccination. The incidence of whooping cough and mortality associated with it corresponded to the official indicators of the Ministry of Health of the Russian Federation. In the base case the time horizon of the study is 12 years. The analysis of the costs of whooping cough therapy was carried out on the basis of the of the State Guarantees Program for the Free Provision of Medical Care to Citizens for 2024 and for the planning period of 2025 and 2026. Vaccination costs were calculated taking into account the weighted average price of the vaccine during government procurement in July-August 2024. Indirect costs were estimated based on gross domestic product (GDP) loss due to temporary disability of patients’ parents and death of patients. Costs and quality-adjusted life expectancy were discounted by 3% per year.Results. The incremental cost-effectiveness ratio (ICER) of revaccination of children aged 6 years against whooping cough is 205.110 thousand rubles / QALY. The volume of averted costs is 2.642 thousand rubles per vaccinated child, including 0.416 thousand rubles – averted direct medical costs and 2.226 thousand rubles – averted indirect costs.Conclusion. Taking into account the accepted assumptions, а booster dose of pertussis vaccine to 6-year-old children can be considered as a highly cost-effective intervention.
- Open Access
- 20 February 2025
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 17 (4) , 504-512
Pharmacoeconomic study of active psoriatic arthritis treatment
Objective: to conduct a clinical and economic analysis of the therapy for adult patients with psoriatic arthritis (PsA) using netakimab, a Russian interleukin-17 inhibitor, in comparison with other biological (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs), available on the pharmaceutical market of the Russian Federation.Material and methods. The evaluation of clinical and economic effectiveness was carried out from the perspective of the healthcare system for a population of patients with active PsA, based on the results of a network meta-analysis. Clinical effectiveness was analyzed through the changes in articular symptoms according to the American College of Rheumatology ACR70 criteria, as well as changes in cutaneous symptoms evaluated by the Psoriasis Area and Severity Index PASI90. A time horizon of the study was set at 2 years. The costs of pharmaceuticals were calculated based on the registered maximum retail prices, inclusive of value-added tax. In case of availability of biosimilars/generics on the market, calculations were based on the minimum values of the registered prices. The impact of price changes on the study results was assessed using sensitivity analysis.Results. According to the network meta-analysis, the efficacy of netakimab at week 24 significantly surpasses that of adalimumab, apremilast, guselkumab, ixekizumab, secukinumab, tofacitinib, ustekinumab, certolizumab pegol, and etanercept in terms of achieving ACR70; netakimab demonstrated a trend towards higher efficacy in comparison with golimumab and infliximab. The netakimab's efficacy appeared significantly greater than that of adalimumab, golimumab, infliximab, secukinumab, ustekinumab, certolizumab pegol, and etanercept with respect to PASI90 criterion; netakimab exhibited a trend towards higher efficacy in comparison with guselkumab and ixekizumab. The observed clinical effect was accompanied by a significant reduction in healthcare system costs: therapy using comparators over a 2-year study horizon was found to be 6–226% costlier than netakimab-based therapy. The expenditure required to achieve a response based on efficacy criteria was minimal among all evaluated regimens when using netakimab. For comparators, the costs to achieve an additional case of response according to the ACR70 criterion were higher by 127.7–894.6%, and by 59.2–2091.3% according to the PASI90 criterion.Conclusion. The treatment regimen for PsA with netakimab is characterized by the lowest cost compared to other bDMARDs and tsDMARDs, while providing better or comparable clinical effect, thereby indicating a higher clinical and economic effectiveness. In order to ensure costs comparable to those associated with netakimab and responses based on ACR70 and PASI90 criteria, substantial reductions in prices of comparators or provision of additional free packages by the manufacturer are required. The inclusion of netakimab in the treatment regimens for PsA significantly enhances an accessibility of therapy and contributes to an improved prognosis for disease course.
- 20 February 2025
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 17 (4) , 504-512
Open AccessPharmacoeconomic study of active psoriatic arthritis treatment
Objective: to conduct a clinical and economic analysis of the therapy for adult patients with psoriatic arthritis (PsA) using netakimab, a Russian interleukin-17 inhibitor, in comparison with other biological (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs), available on the pharmaceutical market of the Russian Federation.Material and methods. The evaluation of clinical and economic effectiveness was carried out from the perspective of the healthcare system for a population of patients with active PsA, based on the results of a network meta-analysis. Clinical effectiveness was analyzed through the changes in articular symptoms according to the American College of Rheumatology ACR70 criteria, as well as changes in cutaneous symptoms evaluated by the Psoriasis Area and Severity Index PASI90. A time horizon of the study was set at 2 years. The costs of pharmaceuticals were calculated based on the registered maximum retail prices, inclusive of value-added tax. In case of availability of biosimilars/generics on the market, calculations were based on the minimum values of the registered prices. The impact of price changes on the study results was assessed using sensitivity analysis.Results. According to the network meta-analysis, the efficacy of netakimab at week 24 significantly surpasses that of adalimumab, apremilast, guselkumab, ixekizumab, secukinumab, tofacitinib, ustekinumab, certolizumab pegol, and etanercept in terms of achieving ACR70; netakimab demonstrated a trend towards higher efficacy in comparison with golimumab and infliximab. The netakimab's efficacy appeared significantly greater than that of adalimumab, golimumab, infliximab, secukinumab, ustekinumab, certolizumab pegol, and etanercept with respect to PASI90 criterion; netakimab exhibited a trend towards higher efficacy in comparison with guselkumab and ixekizumab. The observed clinical effect was accompanied by a significant reduction in healthcare system costs: therapy using comparators over a 2-year study horizon was found to be 6–226% costlier than netakimab-based therapy. The expenditure required to achieve a response based on efficacy criteria was minimal among all evaluated regimens when using netakimab. For comparators, the costs to achieve an additional case of response according to the ACR70 criterion were higher by 127.7–894.6%, and by 59.2–2091.3% according to the PASI90 criterion.Conclusion. The treatment regimen for PsA with netakimab is characterized by the lowest cost compared to other bDMARDs and tsDMARDs, while providing better or comparable clinical effect, thereby indicating a higher clinical and economic effectiveness. In order to ensure costs comparable to those associated with netakimab and responses based on ACR70 and PASI90 criteria, substantial reductions in prices of comparators or provision of additional free packages by the manufacturer are required. The inclusion of netakimab in the treatment regimens for PsA significantly enhances an accessibility of therapy and contributes to an improved prognosis for disease course.
- Open Access
- 20 February 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (1) , 54-64
Experience with the use of undenatured type II collagen in patients with stage III knee osteoarthritis: a multicenter, prospective, double-blind, placebo-controlled, randomized trial
Introduction. Current strategies for treating osteoarthritis (OA) are based on a multimodal approach that includes pharmacological and non-pharmacological methods. Undenatured chicken collagen type II (NK2) is considered safe and effective for maintaining joint health and can be used alone and combined with drugs for OA treatment. Aim. To further evaluate the efficacy of the combination of Artneo containing NK2 in patients with stage III knee OA compared with placebo in a multicenter, prospective, double-blind, placebo-controlled, randomized trial. Materials and methods. The study included 212 patients from 12 centers in the Russian Federation, of whom 50 had radiological stage III knee OA: 41 (82.0%) females and 9 (18.0%) males aged 44 to 75. Using the interactive web response system (IWRS), the study population was randomized into two groups: Group 1 (Artneo group) included 28 patients receiving the drug 1 capsule once a day for 180 days, Group 2 (placebo group) included 22 patients receiving placebo with drug-matched presentation and the same regimen as in Group 1. The effectiveness of therapy was assessed by the change of pain using the Visual Analog Scale, the WOMAC index, KOOS, the EQ-5D quality of life questionnaire, and the need for non-steroidal anti-inflammatory drugs. All patients had a complete blood count, urinalysis, blood chemistry, and ultrasonic examination of the target knee joint. Results. A prospective, double-blind, placebo-controlled, randomized trial demonstrated that Artneo containing NK2 was significantly superior to placebo in all studied parameters, improved all clinical manifestations of OA: reduced pain and stiffness, improved joint function and quality of life, and had a good safety profile. Conclusion. Artneo showed high efficacy and safety in the general population of patients, including those with stage III knee OA.
- 20 February 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (1) , 54-64
Open AccessExperience with the use of undenatured type II collagen in patients with stage III knee osteoarthritis: a multicenter, prospective, double-blind, placebo-controlled, randomized trial
Introduction. Current strategies for treating osteoarthritis (OA) are based on a multimodal approach that includes pharmacological and non-pharmacological methods. Undenatured chicken collagen type II (NK2) is considered safe and effective for maintaining joint health and can be used alone and combined with drugs for OA treatment. Aim. To further evaluate the efficacy of the combination of Artneo containing NK2 in patients with stage III knee OA compared with placebo in a multicenter, prospective, double-blind, placebo-controlled, randomized trial. Materials and methods. The study included 212 patients from 12 centers in the Russian Federation, of whom 50 had radiological stage III knee OA: 41 (82.0%) females and 9 (18.0%) males aged 44 to 75. Using the interactive web response system (IWRS), the study population was randomized into two groups: Group 1 (Artneo group) included 28 patients receiving the drug 1 capsule once a day for 180 days, Group 2 (placebo group) included 22 patients receiving placebo with drug-matched presentation and the same regimen as in Group 1. The effectiveness of therapy was assessed by the change of pain using the Visual Analog Scale, the WOMAC index, KOOS, the EQ-5D quality of life questionnaire, and the need for non-steroidal anti-inflammatory drugs. All patients had a complete blood count, urinalysis, blood chemistry, and ultrasonic examination of the target knee joint. Results. A prospective, double-blind, placebo-controlled, randomized trial demonstrated that Artneo containing NK2 was significantly superior to placebo in all studied parameters, improved all clinical manifestations of OA: reduced pain and stiffness, improved joint function and quality of life, and had a good safety profile. Conclusion. Artneo showed high efficacy and safety in the general population of patients, including those with stage III knee OA.
- Open Access
- 19 February 2025
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 17 (4) , 454-462
Pharmacoeconomic analysis of netakimab in the treatment of ankylosing spondylitis: perspective of Russian healthcare system
Objective: to evaluate clinical and economic effectiveness of netakimab therapy for ankylosing spondylitis (AS) in comparison with other biological disease-modifying antirheumatic drugs (bDMARDs) currently employed in clinical practice in the Russian Federation.Material and methods. The evaluation of clinical and economic effectiveness was carried out from the perspective of the healthcare system based on the results of a network meta-analysis of randomized clinical trials. Clinical effectiveness criteria included indicators of therapeutic response according to the Assessment of Spondyloarthritis International Society criteria, specifically ASAS20 and ASAS40, as well as by the Bath Ankylosing Spondylitis Disease Activity Index BASDAI50. A time horizon of the study was set at 2 years. Costs of pharmaceuticals were calculated according to the registered maximum retail prices, inclusive of value-added tax. In case of availability of biosimilars on the market, calculations were based on the minimum values of the registered prices.Results. According to the network meta-analysis, the efficacy of netakimab significantly surpassed that of other bDMARDs or demonstrated a trend towards higher efficacy for AS. The costs per patient achieving an additional response compared to standard therapy without bDMARDs when treated with netakimab appeared 31–77%, 34–80%, and 20–69% lower than those of other bDMARDs, according to ASAS20, ASAS40, and BASDAI50 criteria, respectively.Conclusion. Netakimab exhibits a higher clinical and economic effectiveness compared to other bDMARDs and may be considered as the preferred therapeutic option in comparable clinical scenarios for active AS, thereby ensuring cost-effectiveness for the healthcare system along with achieving the efficacy criteria compared to the standard treatment regimen. The limitations of the analysis determine the need for further research in this area.
- 19 February 2025
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 17 (4) , 454-462
Open AccessPharmacoeconomic analysis of netakimab in the treatment of ankylosing spondylitis: perspective of Russian healthcare system
Objective: to evaluate clinical and economic effectiveness of netakimab therapy for ankylosing spondylitis (AS) in comparison with other biological disease-modifying antirheumatic drugs (bDMARDs) currently employed in clinical practice in the Russian Federation.Material and methods. The evaluation of clinical and economic effectiveness was carried out from the perspective of the healthcare system based on the results of a network meta-analysis of randomized clinical trials. Clinical effectiveness criteria included indicators of therapeutic response according to the Assessment of Spondyloarthritis International Society criteria, specifically ASAS20 and ASAS40, as well as by the Bath Ankylosing Spondylitis Disease Activity Index BASDAI50. A time horizon of the study was set at 2 years. Costs of pharmaceuticals were calculated according to the registered maximum retail prices, inclusive of value-added tax. In case of availability of biosimilars on the market, calculations were based on the minimum values of the registered prices.Results. According to the network meta-analysis, the efficacy of netakimab significantly surpassed that of other bDMARDs or demonstrated a trend towards higher efficacy for AS. The costs per patient achieving an additional response compared to standard therapy without bDMARDs when treated with netakimab appeared 31–77%, 34–80%, and 20–69% lower than those of other bDMARDs, according to ASAS20, ASAS40, and BASDAI50 criteria, respectively.Conclusion. Netakimab exhibits a higher clinical and economic effectiveness compared to other bDMARDs and may be considered as the preferred therapeutic option in comparable clinical scenarios for active AS, thereby ensuring cost-effectiveness for the healthcare system along with achieving the efficacy criteria compared to the standard treatment regimen. The limitations of the analysis determine the need for further research in this area.
- Open Access
- 27 December 2024
- Published by SPRIDA in Journal Infectology
- Vol. 16 (4) , 99-104
Cost-effectiveness of vaccination against HPV of adolescent girls in the regions of Russian Federation
Vaccination against human papillomavirus infection is not included in the National Calendar of Preventive Vaccinations of the Russian Federation, and vaccination is only available through regional programs. At the same time, the costeffectiveness of vaccination in the regions of the Russian Federation may vary significantly.The aim of this study was to assess the costeffectiveness of vaccination with the 4valent HPV vaccine in 12yearold girls in the regions of the Russian Federation.Materials and methods. A Markov model with a lifetime horizon for 12yearold girls based on epidemiological data for the Russian Federation was used. The costeffectiveness analysis was carried out from societal perspective. Costs and life expectancy were discounted at 3% per year.Results. In most regions of the Russian Federation, vaccination of girls is cost saving or highly costeffective (the cost per additional qualityadjusted life year (QALY) does not exceed the value of gross regional product per capita). Only in Dagestan, Chechnya and Ingushetia the vaccination of girls can be considered as costeffective, but not highly costeffective tool (incremental costs per QALY exceed the GRP per capita by 14,237,0%).Conclusions. Vaccination of girls before the onset of sexual activity with the 4valent HPV vaccine is highly costeffective in most regions of the Russian Federation.
- 27 December 2024
- Published by SPRIDA in Journal Infectology
- Vol. 16 (4) , 99-104
Open AccessCost-effectiveness of vaccination against HPV of adolescent girls in the regions of Russian Federation
Vaccination against human papillomavirus infection is not included in the National Calendar of Preventive Vaccinations of the Russian Federation, and vaccination is only available through regional programs. At the same time, the costeffectiveness of vaccination in the regions of the Russian Federation may vary significantly.The aim of this study was to assess the costeffectiveness of vaccination with the 4valent HPV vaccine in 12yearold girls in the regions of the Russian Federation.Materials and methods. A Markov model with a lifetime horizon for 12yearold girls based on epidemiological data for the Russian Federation was used. The costeffectiveness analysis was carried out from societal perspective. Costs and life expectancy were discounted at 3% per year.Results. In most regions of the Russian Federation, vaccination of girls is cost saving or highly costeffective (the cost per additional qualityadjusted life year (QALY) does not exceed the value of gross regional product per capita). Only in Dagestan, Chechnya and Ingushetia the vaccination of girls can be considered as costeffective, but not highly costeffective tool (incremental costs per QALY exceed the GRP per capita by 14,237,0%).Conclusions. Vaccination of girls before the onset of sexual activity with the 4valent HPV vaccine is highly costeffective in most regions of the Russian Federation.